Efficacy of azathioprine for all patients with ITP
| . | n (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Patients who received azathioprine (N = 92) . | Patients who did not receive TPO-RA before azathioprine (n = 86) . | Patients who received TPO-RA before azathioprine (n = 6) . | P value∗ . | Patients who did not receive splenectomy before azathioprine (n = 65) . | Patients who received splenectomy before azathioprine (n = 27) . | P value† . | |
| Response achieved | .948 | .259 | |||||
| ORR | 44 (47.8%) | 41 (47.7%) | 3 (50%) | 33 (50.8%) | 11 (40.7%) | ||
| CR | 35 (38.0%) | 33 (38.4%) | 2 (33.3%) | 26 (40.0%) | 9 (33.3%) | ||
| R | 9 (9.8%) | 8 (9.3%) | 1 (16.7%) | 7 (10.8%) | 2 (7.4%) | ||
| NR | 32 (34.8%) | 29 (33.7%) | 2 (33.3%) | 24 (36.9%) | 8 (29.6%) | ||
| Intolerant (I) | 16 (17.4%) | 16 (18.6%) | 1 (16.7%) | 8 (12.3%) | 8 (29.6%) | ||
| Time to response‡, median (range), wk | 6 (4-27) | 6 (4-27) | 5 (4-10) | .588 | 6 (4-13) | 6 (4-27) | .186 |
| Relapse§ | 14 (31.8%) | 13 (31.7%) | 1 (33.3%) | N/A | 13 (39.4%) | 1 (9.1%) | N/A |
| Duration of response||, median (range), wk | 10 (1-123) | 10 (1-87) | 123 | N/A | 10 (1-87) | 123 | N/A |
| . | n (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Patients who received azathioprine (N = 92) . | Patients who did not receive TPO-RA before azathioprine (n = 86) . | Patients who received TPO-RA before azathioprine (n = 6) . | P value∗ . | Patients who did not receive splenectomy before azathioprine (n = 65) . | Patients who received splenectomy before azathioprine (n = 27) . | P value† . | |
| Response achieved | .948 | .259 | |||||
| ORR | 44 (47.8%) | 41 (47.7%) | 3 (50%) | 33 (50.8%) | 11 (40.7%) | ||
| CR | 35 (38.0%) | 33 (38.4%) | 2 (33.3%) | 26 (40.0%) | 9 (33.3%) | ||
| R | 9 (9.8%) | 8 (9.3%) | 1 (16.7%) | 7 (10.8%) | 2 (7.4%) | ||
| NR | 32 (34.8%) | 29 (33.7%) | 2 (33.3%) | 24 (36.9%) | 8 (29.6%) | ||
| Intolerant (I) | 16 (17.4%) | 16 (18.6%) | 1 (16.7%) | 8 (12.3%) | 8 (29.6%) | ||
| Time to response‡, median (range), wk | 6 (4-27) | 6 (4-27) | 5 (4-10) | .588 | 6 (4-13) | 6 (4-27) | .186 |
| Relapse§ | 14 (31.8%) | 13 (31.7%) | 1 (33.3%) | N/A | 13 (39.4%) | 1 (9.1%) | N/A |
| Duration of response||, median (range), wk | 10 (1-123) | 10 (1-87) | 123 | N/A | 10 (1-87) | 123 | N/A |
CR was defined as platelet count ≥100 × 109/L and absence of bleeding; R, platelet count ≥30 × 109/L and at least twofold increase the baseline count and absence of bleeding; NR, platelet count <30 × 109/L or less than twofold increase of baseline platelet count or bleeding.Intolerant includes patients who discontinued azathioprine before reaching a minimum of 4 weeks, which is the first time that a response to azathioprine could be reasonably expected. N/A represents “not applicable” due to 1 group having an array size of n = 1.
NR, no response.
Calculated between patients who received TPO-RA before azathioprine and those who did not.
Calculated between patients who had a splenectomy before azathioprine and those who did not.
Defined as time from the start of azathioprine to CR or R.
Patients who lost CR or R while still on azathioprine.
Defined as time from the achievement of CR or R to relapse.